
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3008026/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway. Aging, 2020, 12, 24270-24287.	3.1	149
2	The <scp>HASâ€BLED</scp> Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Metaâ€analysis. Clinical Cardiology, 2015, 38, 555-561.	1.8	141
3	Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis. Cardiovascular Diabetology, 2022, 21, .	6.8	73
4	Association of smoking with the risk of incident atrial fibrillation: A meta-analysis of prospective studies. International Journal of Cardiology, 2016, 218, 259-266.	1.7	67
5	Relation of Body Mass Index With Adverse Outcomes Among Patients With Atrial Fibrillation: A Metaâ€Analysis and Systematic Review. Journal of the American Heart Association, 2016, 5, .	3.7	66
6	Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation Across BMI Categories: A Systematic Review and Meta-Analysis. American Journal of Cardiovascular Drugs, 2020, 20, 51-60.	2.2	60
7	Fluoroquinolones increase the risk of serious arrhythmias. Medicine (United States), 2017, 96, e8273.	1.0	54
8	Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs. Nutrition Journal, 2021, 20, 89.	3.4	53
9	Genotype-phenotype relationship in patients with arrhythmogenic right ventricular cardiomyopathy caused by desmosomal gene mutations: A systematic review and meta-analysis. Scientific Reports, 2017, 7, 41387.	3.3	36
10	The obesity paradox for outcomes in atrial fibrillation: Evidence from an exposureâ€effect analysis of prospective studies. Obesity Reviews, 2020, 21, e12970.	6.5	35
11	Prevalence of Atrial Fibrillation and Associated Mortality Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 720129.	2.4	34
12	Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 757087.	2.4	32
13	Meta-analysis of ATRIA versus CHA2DS2-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. International Journal of Cardiology, 2017, 227, 436-442.	1.7	29
14	O-GlcNAcylation of cardiac Nav1.5 contributes to the development of arrhythmias in diabetic hearts. International Journal of Cardiology, 2018, 260, 74-81.	1.7	27
15	Can ventricular tachycardia non-inducibility after ablation predict reduced ventricular tachycardia recurrence and mortality in patients with non-ischemic cardiomyopathy? A meta-analysis of twenty-four observational studies. International Journal of Cardiology, 2016, 222, 689-695.	1.7	26
16	Resting Heart Rate and the Risk of Atrial Fibrillation. International Heart Journal, 2019, 60, 805-811.	1.0	26
17	Comparative Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients. Stroke, 2021, 52, 1225-1233.	2.0	26
18	Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. Oncotarget, 2017, 8, 109703-109711.	1.8	24

#	Article	IF	CITATIONS
19	Sevoflurane postconditioning reduces myocardial ischemia reperfusion injury-induced necroptosis by up-regulation of OGT-mediated O-GlcNAcylated RIPK3. Aging, 2020, 12, 25452-25468.	3.1	23
20	Association of Physical Fitness With the Risk of Atrial Fibrillation: A Systematic Review and Metaâ€Analysis. Clinical Cardiology, 2016, 39, 421-428.	1.8	22
21	Hydrogen sulfide restores sevoflurane postconditioning mediated cardioprotection in diabetic rats: Role of SIRT1/Nrf2 signalingâ€modulated mitochondrial dysfunction and oxidative stress. Journal of Cellular Physiology, 2021, 236, 5052-5068.	4.1	22
22	Brugada syndrome with SCN5A mutations exhibits more pronounced electrophysiological defects and more severe prognosis: A metaâ€analysis. Clinical Genetics, 2020, 97, 198-208.	2.0	21
23	Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4–5 Chronic Kidney Disease or on Dialysis. Cardiovascular Drugs and Therapy, 2021, 35, 273-281.	2.6	19
24	Relationship between retinal vascular occlusions and incident cerebrovascular diseases. Medicine (United States), 2016, 95, e4075.	1.0	17
25	Do Implantable Cardioverter Defibrillators Reduce Mortality in Patients With Chronic Kidney Disease at All Stages?. International Heart Journal, 2017, 58, 371-377.	1.0	17
26	The Prevalence and Associated Death of Ventricular Arrhythmia and Sudden Cardiac Death in Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 795750.	2.4	17
27	Potential Cardiovascular Risks of Proton Pump Inhibitors in the General Population. International Heart Journal, 2017, 58, 163-166.	1.0	16
28	Ankyrin-B Q1283H Variant Linked to Arrhythmias Via Loss of Local Protein Phosphatase 2A Activity Causes Ryanodine Receptor Hyperphosphorylation. Circulation, 2018, 138, 2682-2697.	1.6	16
29	A mutation in the CACNA1C gene leads to early repolarization syndrome with incomplete penetrance: A Chinese family study. PLoS ONE, 2017, 12, e0177532.	2.5	15
30	Real-World Relationship Between Proton Pump Inhibitors and Cerebro-Cardiovascular Outcomes Independent of Clopidogrel. International Heart Journal, 2019, 60, 910-918.	1.0	15
31	Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review. American Journal of Cardiovascular Drugs, 2020, 20, 139-147.	2.2	15
32	Non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: evidences from the real-world data. Heart Failure Reviews, 2020, 25, 957-964.	3.9	15
33	Relationship between smoking and adverse outcomes in patients with atrial fibrillation: A meta-analysis and systematic review. International Journal of Cardiology, 2016, 222, 289-294.	1.7	14
34	Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 2020, 50, 311-317.	2.1	13
35	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Peripheral Artery Disease: a Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy, 2020, 34, 391-399.	2.6	13
36	Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial. British Journal of General Practice, 2021, 71, e62-e70.	1.4	13

#	Article	IF	CITATIONS
37	C2HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial. BMC Medicine, 2021, 19, 44.	5.5	11
38	Effectiveness and Safety of DOACs vs. VKAs in AF Patients With Cancer: Evidence From Randomized Clinical Trials and Observational Studies. Frontiers in Cardiovascular Medicine, 2021, 8, 766377.	2.4	11
39	Association of body mass index and all-cause mortality in patients after cardiac surgery: A dose-response meta-analysis. Nutrition, 2020, 72, 110696.	2.4	10
40	Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	10
41	Effect of anticoagulation therapy in older patients with chronic kidney disease and atrial fibrillation. Medicine (United States), 2019, 98, e17628.	1.0	9
42	Usefulness of CHADS2, R2CHADS2, and CHA2DS2â€VASc scores for predicting incident atrial fibrillation in heart failure with preserved ejection fraction patients. ESC Heart Failure, 2021, 8, 1369-1377.	3.1	9
43	CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Cardiovascular Drugs and Therapy, 2020, 34, 763-772.	2.6	8
44	Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies. Cardiovascular Drugs and Therapy, 2020, 34, 569-578.	2.6	8
45	Efficacy and safety of triple versus dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis. Oncotarget, 2017, 8, 81154-81166.	1.8	7
46	Weight Change and Mortality Risk in Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 681726.	2.4	7
47	Sex-Specific Exposure–Effect Relationship Between Physical Activity and Incident Atrial Fibrillation in the General Population: A Dose–Response Meta-Analysis of 16 Prospective Studies. Frontiers in Cardiovascular Medicine, 2021, 8, 710071.	2.4	7
48	Variant rs2200733 and rs10033464 on chromosome 4q25 are associated with increased risk of atrial fibrillation after catheter ablation: Evidence from a meta-analysis. Cardiology Journal, 2018, 25, 628-638.	1.2	7
49	Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials. American Journal of Cardiovascular Drugs, 2019, 19, 37-47.	2.2	6
50	Living Alone and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Psychosomatic Medicine, 2021, 83, 470-476.	2.0	6
51	Major depression and clinical outcomes in patients with heart failure with preserved ejection fraction. European Journal of Clinical Investigation, 2021, 51, e13401.	3.4	6
52	Genotype-based clinical manifestation and treatment of Chinese long QT syndrome patients with <i>KCNQ1</i> mutations – R380S and W305L. Cardiology in the Young, 2016, 26, 754-763.	0.8	5
53	Association of physical activity and risk of atrial fibrillation in heart failure with preserved ejection fraction. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 247-253.	2.6	5
54	Association of Body-Weight Fluctuation With Outcomes in Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 689591.	2.4	5

#	Article	IF	CITATIONS
55	Reappraisal of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 757188.	2.4	5
56	The "Obesity Paradox―in Patients With HFpEF With or Without Comorbid Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 2021, 8, 743327.	2.4	5
57	Association of Depression, Antidepressants With Atrial Fibrillation Risk: A Systemic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	5
58	Association of long-term SBP with clinical outcomes and quality of life in heart failure with preserved ejection fraction: an analysis of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Journal of Hypertension, 2021, 39, 1378-1385.	0.5	4
59	Association of body mass index and prognosis in patients with HFpEF: A dose-response meta-analysis. International Journal of Cardiology, 2022, 361, 40-46.	1.7	4
60	Offâ€label underdosing of four individual <scp>NOACs</scp> in patients with nonvalvular atrial fibrillation: A systematic review and metaâ€analysis of observational studies. European Journal of Clinical Investigation, 2022, 52, .	3.4	4
61	Dose-response relationship of cardiorespiratory fitness with incident atrial fibrillation. Heart Failure Reviews, 2020, 25, 419-425.	3.9	3
62	Sex-Specific Associations of Risks and Cardiac Structure and Function With Microalbumin/Creatinine Ratio in Diastolic Heart Failure. Frontiers in Cardiovascular Medicine, 2020, 7, 579400.	2.4	2
63	Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT. ESC Heart Failure, 2020, 7, 3801-3809.	3.1	2
64	Associations of BMI with mortality in HFpEF patients with concomitant diabetes with insulin versus non-insulin treatment. Diabetes Research and Clinical Practice, 2022, 185, 109805.	2.8	2
65	Associations of Antidepressants With Atrial Fibrillation and Ventricular Arrhythmias: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 840452.	2.4	2
66	Impact of COPD or Asthma on the Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 872446.	2.4	2
67	GW27-e0836 Association of smoking with the risk of incident atrial fibrillation: a meta-analysis of prospective studies. Journal of the American College of Cardiology, 2016, 68, C75-C76.	2.8	1
68	Role of Second-Generation Drug-Eluting Stents and Bypass Grafting in Coronary Artery Disease: A Systematic Review and Meta-analysis. Cardiovascular Innovations and Applications, 2017, 2, .	0.3	0
69	Author's Reply to Vaz et al.: "Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease― American Journal of Cardiovascular Drugs, 2020, 20, 507-508.	2.2	0
70	Direct Oral Anticoagulants vs. Warfarin in Latin American Patients With Atrial Fibrillation: Evidence From Four post-hoc Analyses of Randomized Clinical Trials. Frontiers in Cardiovascular Medicine, 2022, 9, 841341.	2.4	0